Ricoux A, Guitteny-Collas M, Sauvaget A, Delvot P, Pottier P, Hamidou M, Vanelle J-M
Service de psychiatrie 4, hôpital Saint-Jacques, CHU de Nantes, 85, rue Saint-Jacques, 44093 Nantes cedex 1, France.
Rev Med Interne. 2013 May;34(5):293-302. doi: 10.1016/j.revmed.2012.12.011. Epub 2013 Jan 30.
Oral glucocorticoids have been used for several decades and psychiatric side-effects may occur. This review will discuss relevant data of the clinical specificities, the incidence, the risk factors for the occurrence of these episodes and the preventive and curative medications of these episodes. We performed a literature review by using PubMed database. We selected and discussed articles and studies with high standard of evidence. The occurrence of psychiatric symptoms is quite frequent. The varying intensity of clinical features ranges from minor signs (impregnation) to acute psychotic episodes which may occur from 5 to 30% of patients. Affective symptoms or disorders are the most prominent clinical features. Delirium may occur and suicidal risk could be increased. The significant predictive factors are prednisone dosage more than 40 mg/day, particularly weight-based dosage, and a history of psychiatric disorders. When a reduced dosage of glucocorticoids is not sufficient to control the symptomatology, curative medication is mainly based on atypical antipsychotics such as olanzapine. Studies about neuropsychiatric complications of glucocorticoids present various and heterogeneous results. Further prospective clinical studies should be based on a close cooperation between physicians and consultation liaison psychiatrists. This collaboration is required for an optimized management of the patient who receive glucocorticoids.
口服糖皮质激素已使用数十年,可能会出现精神方面的副作用。本综述将讨论这些情况的临床特异性、发生率、发生这些事件的风险因素以及针对这些事件的预防和治疗药物的相关数据。我们通过使用PubMed数据库进行了文献综述。我们挑选并讨论了具有高证据标准的文章和研究。精神症状的发生相当频繁。临床特征的强度各不相同,从轻微症状(浸润)到急性精神病发作,可能出现在5%至30%的患者中。情感症状或障碍是最突出的临床特征。可能会出现谵妄,自杀风险可能会增加。重要的预测因素是泼尼松剂量超过40毫克/天,尤其是基于体重的剂量,以及有精神疾病史。当减少糖皮质激素剂量不足以控制症状时,治疗药物主要基于非典型抗精神病药物,如奥氮平。关于糖皮质激素神经精神并发症的研究呈现出多样且异质的结果。进一步的前瞻性临床研究应基于医生与会诊联络精神科医生之间的密切合作。这种合作对于优化接受糖皮质激素治疗患者的管理是必要的。